Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

6.74
+0.790013.28%
Post-market: 6.790.0500+0.74%19:44 EST
Volume:867.20K
Turnover:5.74M
Market Cap:356.92M
PE:-8.67
High:6.87
Open:6.09
Low:6.06
Close:5.95
52wk High:7.73
52wk Low:1.34
Shares:52.96M
Float Shares:41.44M
Volume Ratio:1.07
T/O Rate:2.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.7641
ROE:-182.55%
ROA:-66.48%
PB:43.18
PE(LYR):-8.82

Loading ...

Company Profile

Company Name:
Immix Biopharma, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
20
Office Location:
11400 West Olympic Boulevard,Suite 200,Los Angeles,California,United States
Zip Code:
90064
Fax:
- -
Introduction:
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Directors

Name
Position
Ilya Rachman
Chairman of the Board and Chief Executive Officer
Carey Ng
Independent Director
Gabriel Morris
Chief Financial Officer, Principal Accounting Officer and Director
Helen C. Adams
Independent Director
Jane M. Buchan
Independent Director
Jason Hsu
Independent Director
Magda Marquet
Independent Director
Yekaterina Chudnovsky
Independent Director
Nancy Chang
Director

Shareholders

Name
Position
Ilya Rachman
Chairman of the Board and Chief Executive Officer
Gabriel Morris
Chief Financial Officer, Principal Accounting Officer and Director
Graham Ross
Acting Chief Medical Officer and Head of Clinical Development
Vladimir Torchilin
Scientific Co-Founder